Low electric field enhanced chemotherapy can cure mice with CT‐26 colon carcinoma and induce anti‐tumour immunity

• Published in: Clinical and experimental immunology Vol. 138; no. 3; pp. 410 - 416
• Main Authors: PLOTNIKOV, A., FISHMAN, D., TICHLER, T., KORENSTEIN, R., KEISARI, Y.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01-12-2004; Blackwell; Oxford University Press; Blackwell Science Inc
• Subjects: Animal Studies; Animals; Antimetabolites, Antineoplastic - therapeutic use; Antineoplastic Agents - therapeutic use; Antineoplastic Agents, Alkylating - therapeutic use; Biological and medical sciences; Bleomycin - therapeutic use; Carmustine - therapeutic use; Cell Line, Tumor; chemotherapy; colon cancer; Colonic Neoplasms - drug therapy; Colonic Neoplasms - immunology; Electromagnetic Fields; electrostimulation; Fluorouracil - therapeutic use; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Immunopathology; immunostimulation; low electric field; Male; Medical sciences; Mice; Mice, Inbred BALB C; Spleen - cytology; Spleen - immunology; Antineoplastic agent; Immunopathology; Immunostimulation; Cure; Electrical stimulus; Rodentia; Malignant tumor; Immunity; Colonic disease; Vertebrata; Chemotherapy; Mammalia; Electric field; Immunology; Treatment; Colon cancer; Mouse; Animal; Digestive diseases; Intestinal disease; Colon carcinoma; chemotherapy colon cancer electrostimulation immunostimulation low electric field
• ISSN: 0009-9104; 1365-2249
• DOI: 10.1111/j.1365-2249.2004.02636.x

SUMMARY
Low electric field cancer treatment − enhanced chemotherapy (LEFCT‐EC) is a new anticancer treatment which utilizes a combination of chemotherapeutic agents and a low electric field. We investigated the antitumour effectiveness of this technique in a model of murine colon carcinoma (CT‐26). The low electric field was applied to ∼ 65 mm3 intracutaneous tumours after intratumoral injection of 5FU, bleomycin or BCNU. We observed significant tumour size reduction and a prolongation of survival time. The complete cure of a significant fraction of animals treated by LEFCT‐EC with 5FU (33%), bleomycin (51%) or BCNU (83%) was observed. Mice cured by LEFCT‐EC developed resistance to a tumour challenge and their splenocytes had antitumour activity in vivo. Our results suggest that LEFCT‐EC is an effective method for treatment of solid tumours.